Get startedLog in
    Picture of Disruptive Pharma AB (publ) logo

    DPHA — Disruptive Pharma AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Guard Therapeutics International Gets Approval To Conduct Clinical Study Of RMC-035 In Kidney Transplantation

    Picture of Disruptive Pharma AB (publ) logoDisruptive Pharma AB (publ)
    01/06/2022 15:31
    June 1 (Reuters) - Guard Therapeutics International AB (publ)  GUARD.ST :
    * RECEIVES APPROVAL FROM SWEDISH MEDICAL PRODUCTS AGENCY TO CONDUCT A CLINICAL STUDY OF
RMC-035 IN
KIDNEY TRANSPLANTATION
    * IS EXPECTED TO PRESENT FULL STUDY RESULTS IN H1 2023

Source text for Eikon:  ID:nMFN1WhzTq 
Further company coverage:  GUARD.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Disruptive Pharma AB (publ)

    See all news